OPDUALAG
Total Payments
$18.8M
Transactions
13,654
Doctors
4,694
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $5.4M | 5,671 | 2,655 |
| 2023 | $13.4M | 7,844 | 3,463 |
| 2022 | $3,637 | 139 | 129 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $18.6M | 413 | 98.7% |
| Food and Beverage | $225,258 | 13,107 | 1.2% |
| Grant | $10,000 | 1 | 0.1% |
| Education | $3,291 | 131 | 0.0% |
| Consulting Fee | $2,325 | 1 | 0.0% |
| Travel and Lodging | $79.75 | 1 | 0.0% |
Payments by Type
Research
$18.6M
413 transactions
General
$240,953
13,241 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| PhII 1L HCC Rela+Nivo+Bev vs Nivo+Bev - A Phase 1/2, Safety Confirmation, Placebo-controlled, Randomized Study of Nivolumab in Combination with Relatlimab and Bevacizumab in Treatment-naive Advanced/Metastatic Hepatocellular Carcinoma | E.R. Squibb & Sons, L.L.C. | $4.1M | 3 |
| PhIII Stage 3/4 Resectable Mel Adj Rela+Nivo vs Nivo - A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Relatlimab andNivolumab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma [ | E.R. Squibb & Sons, L.L.C. | $3.5M | 0 |
| Phase III MSS 3L CRC Rela+Nivo vs. regorafenib/TAS-102 - A Phase III, Randomized, Sponsor Blinded Study of Relatlimab-Nivolumab Fixed Dosed Combination versus Regorafenib or Trifluridine plus Tipiracil for Participants with Later-Lines of Metastatic Color | E.R. Squibb & Sons, L.L.C. | $2.3M | 2 |
| Phase III 1L Melanoma non-inferiority rela+nivo FDC SubQ vs. rela+nivo FDC IV | E.R. Squibb & Sons, L.L.C. | $1.7M | 0 |
| Ph II/III IO Naive Mel (lag3 + nivo FDC) - A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma | E.R. Squibb & Sons, L.L.C. | $1.3M | 0 |
| A Phase 2 Randomized Double-blind Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) | E.R. Squibb & Sons, L.L.C. | $1.0M | 0 |
| Ph I/II mono (lag3) vs combo (lag3 + nivo) (solid tumors) | E.R. Squibb & Sons, L.L.C. | $769,986 | 0 |
| A Phase 2 study Evaluating Response and Biomarkers in Patients with Microsatellite Stable MSS Advanced Colorectal Cancer treated with Nivolumab in Combination with Relatlimab | E.R. Squibb & Sons, L.L.C. | $545,719 | 0 |
| Phase II Study of Nivolumab in Combination with Relatlimab in Patients with Active Melanoma Brain Metastases | E.R. Squibb & Sons, L.L.C. | $514,191 | 0 |
| Ph II Study Gastric 1L, multi-cohort all comers (lag3 + nivo) | E.R. Squibb & Sons, L.L.C. | $395,423 | 0 |
| The immune landscape of the tumor microenvironment and its influence on therapeutic outcomes in the setting of Relatlimab therapy: Contrasting MxIF profiles in melanoma and gastric cancer | E.R. Squibb & Sons, L.L.C. | $351,000 | 0 |
| PhI/II Other I-O (Triplet) (lag3 + nivo + ipi vs lag3 + nivo + IDO) - A Phase 1/2 Study of Relatlimab (anti-LAG-3 Monoclonal Antibody) Administered in Combination with Both Nivolumab (anti-PD-1 Monoclonal Antibody) and BMS- 986205 (IDO1 inhibitor) or in C | E.R. Squibb & Sons, L.L.C. | $341,096 | 0 |
| Phase II neoadjuvant study of the safety and tolerability of anti-LAG3 (relatlimab) administered in combination with anti-PD1 (nivolumab) and anti-CTLA4 (ipilimumab) in resectable head and neck cancer | E.R. Squibb & Sons, L.L.C. | $294,428 | 0 |
| A phase II trial of personalized immunotherapy in recurrent/metastatic HNSCC | E.R. Squibb & Sons, L.L.C. | $211,770 | 0 |
| Ph I Pk multitumor SubQ formulation Relatlimab | E.R. Squibb & Sons, L.L.C. | $205,411 | 0 |
| Ph I/II Mono (lag3 ) and combo (lag3 + nivo) (heme malignancies) | E.R. Squibb & Sons, L.L.C. | $204,748 | 0 |
| To characterize the mechanisms of action/resistance of anti-LAG-3 antibody (Ab)-mediated anti-cancer therapy and to identify the optimum combination partners for anti-LAG-3 Ab. | E.R. Squibb & Sons, L.L.C. | $198,111 | 0 |
| Ph II Melanoma rela+ipi combo - A Phase 1/2a Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab Administered in Combination with Ipilimumab or Ipilimumab Alone in Participants with Unresectable or Metastatic Melanoma Who Have Progresse | E.R. Squibb & Sons, L.L.C. | $165,200 | 0 |
| A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer (RELATIVITY-123) | E.R. Squibb & Sons, L.L.C. | $153,199 | 0 |
| A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants With Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma | E.R. Squibb & Sons, L.L.C. | $127,851 | 0 |
Top Doctors Receiving Payments for OPDUALAG
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Ashok Sharma | — | Ridgewood, NJ | $18.4M | 416 |
| , MD | Nuclear Radiology | Bethlehem, PA | $68,022 | 4 |
| , M.D | Diagnostic Radiology | Boston, MA | $66,425 | 2 |
| , M.D | Body Imaging | Vero Beach, FL | $45,165 | 4 |
| , MD | Diagnostic Radiology | New York, NY | $10,446 | 2 |
| , MD | Hematology & Oncology | Cleveland, OH | $2,325 | 1 |
| , M.D.;PH.D | Diagnostic Radiology | New York, NY | $600.00 | 1 |
| , M.D | Student in an Organized Health Care Education/Training Program | New York, NY | $447.50 | 1 |
| , M.D | Hematology & Oncology | Houston, TX | $314.52 | 13 |
| , NP | Acute Care | Houston, TX | $309.67 | 17 |
| , M. D | Medical Oncology | Sugar Land, TX | $302.08 | 12 |
| , M.D | Hematology & Oncology | Lakewood, WA | $301.28 | 15 |
| Pete Pow-Anpongkul | Internal Medicine | Los Alamitos, CA | $298.58 | 17 |
| , NP | Nurse Practitioner | Pearland, TX | $297.05 | 12 |
| , M.D | Hematology & Oncology | El Segundo, CA | $295.01 | 17 |
| , MD, PHD | Medical Oncology | Olympia, WA | $279.16 | 14 |
| , MD | Medical Oncology | Homestead, FL | $277.33 | 5 |
| , M.D | Hematology & Oncology | Los Alamitos, CA | $276.64 | 19 |
| , MD | Hematology & Oncology | Los Angeles, CA | $275.73 | 24 |
| , MD | Specialist | Los Alamitos, CA | $270.12 | 18 |
| , NP | Family | Birmingham, AL | $269.24 | 20 |
| , M.D | Hematology & Oncology | San Antonio, TX | $267.40 | 12 |
| , APRN | Family | Louisville, KY | $266.40 | 26 |
| , MD | Specialist | Cerritos, CA | $263.31 | 14 |
| , M.D., PH.D | Hematology & Oncology | Renton, WA | $262.04 | 11 |
Ad
Manufacturing Companies
- E.R. Squibb & Sons, L.L.C. $18.7M
- Celgene Corporation $71,795
Product Information
- Type Drug
- Total Payments $18.8M
- Total Doctors 4,694
- Transactions 13,654
About OPDUALAG
OPDUALAG is a drug associated with $18.8M in payments to 4,694 healthcare providers, recorded across 13,654 transactions in the CMS Open Payments database. The primary manufacturer is E.R. Squibb & Sons, L.L.C..
Payment data is available from 2022 to 2024. In 2024, $5.4M was paid across 5,671 transactions to 2,655 doctors.
The most common payment nature for OPDUALAG is "Unspecified" ($18.6M, 98.7% of total).
OPDUALAG is associated with 20 research studies, including "PhII 1L HCC Rela+Nivo+Bev vs Nivo+Bev - A Phase 1/2, Safety Confirmation, Placebo-controlled, Randomized Study of Nivolumab in Combination with Relatlimab and Bevacizumab in Treatment-naive Advanced/Metastatic Hepatocellular Carcinoma" ($4.1M).